2seventy bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

2seventy bio, Inc. (NASDAQ: TSVT) has announced participation in two key investor conferences. The first is the Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 PM ET, where they will join a panel discussion titled “A View to a Kill(er Cell) – Part 1.” The second event is the 42nd Annual Canaccord Genuity Growth Conference on August 11, 2022, at 2:30 PM ET in Boston, MA. Live webcasts will be available on 2seventy bio’s website, with replays archived for 30 days post-event.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences:

• 2022 Wedbush PacGrow Healthcare Conference, “A View to a Kill(er Cell) – Part 1” panel on Wednesday, August 10, 2022 at 1:10 pm ET
• 42nd Annual Canaccord Genuity Growth Conference, fireside chat on Thursday, August 11, 2022 at 2:30 pm ET, the InterContinental Boston, Boston, MA

A live webcast will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. A replay will be archived on 2seventy bio’s site for 30 days following the event.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: Twitter and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005570/en/

Investors:

Jenn Snyder, 617-448-0281

Jenn.snyder@2seventybio.com

Media:

Morgan Adams, 774-313-9852

morgan.adams@2seventybio.com

Source: 2seventy bio, Inc.

FAQ

What investor conferences is 2seventy bio participating in August 2022?

2seventy bio will participate in the Wedbush PacGrow Healthcare Conference on August 10, 2022, and the Canaccord Genuity Growth Conference on August 11, 2022.

What is the schedule for 2seventy bio's investor conferences in August 2022?

The Wedbush PacGrow Healthcare Conference is on August 10, 2022, at 1:10 PM ET, and the Canaccord Genuity Growth Conference is on August 11, 2022, at 2:30 PM ET.

Where can I watch the investor conferences for 2seventy bio?

Live webcasts of the investor conferences will be available on 2seventy bio's website, with replays archived for 30 days after each event.

What is the main focus of 2seventy bio, Inc.?

2seventy bio focuses on developing immuno-oncology cell therapies to treat various cancers, including hematologic malignancies and solid tumors.